Anemia is a common complication in patients with chronic kidney disease (CKD). In addition to
erythropoietin deficiency, many studies have identified iron deficiency as a cause of anemia
in CKD patients. Most patients with CKD are iron deficient because of: inadequate intake and
absorption, gastroenteric bleeding, urinary iron loss in patient with significant
proteinuria. The iron treatment is pivotal to manage anemic patients with CKD: the
prescription of iron is usually oral because of practicality and safety, but often it is
inevitable to administer intravenous iron because of gastroenteric malabsorption, intolerance
to oral administration, irregular intake. There're few randomized controlled studies about
the efficacy of oral iron versus intravenous iron in patients not on dialysis; most of them
demonstrate superiority of intravenous therapy to restore iron deficiency and hemoglobin
levels. A particular formulation of iron, liposomal iron has a high gastroenteric absorption
and high bioavailability with lower incidence of side effects. The investigators study aims
to evaluate the efficacy of treatment with liposomal oral iron compared to intravenous iron
in CKD anemic patients not on dialysis in the presence of iron deficiency.